Tempus AI Acquires Paige to Enhance Digital Pathology and Advance Precision Medicine
Tempus AI, Inc. has acquired Paige, an AI company in digital pathology, for $81.25 million. This acquisition aims to enhance Tempus's dataset and technical team, strengthening its position in digital pathology. The deal primarily involves payment in Tempus common stock and includes Paige's cloud services agreement with Microsoft Azure. Paige's collaboration with Memorial Sloan Kettering Cancer Center provides valuable data, expected to accelerate Tempus's oncology model development.
Tempus AI, Inc. has announced its acquisition of Paige, an AI company specializing in digital pathology, for $81.25 million. This strategic move is aimed at enhancing Tempus’s dataset, expanding its technical team, and strengthening its position in digital pathology. The acquisition predominantly involves payment in Tempus common stock and the assumption of Paige’s cloud services agreement with Microsoft Azure. Paige, known for its AI applications in pathology, brings a valuable dataset from its collaboration with Memorial Sloan Kettering Cancer Center. This acquisition is expected to accelerate Tempus’s efforts in building a substantial foundation model in oncology, leveraging Paige’s expertise and comprehensive dataset. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250822422844) on August 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
